

Call: H2020-SC1-2018-Single-Stage-RTD
Topic: SC1-BHC-09-2018
Funding Scheme: Research & Innovation Action (RIA)



Deliverable No. 12.1

Public project website

Grant Agreement no.:	825828
Project Title:	EXpanding Platforms for Efficacious mRNA Therapeutics
Contractual Submission Date:	31/10/2019
Actual Submission Date:	31/10/2019
Responsible partner:	P11: European Research and Project Office GmbH (Eurice)

Grant agreement no.	825828
Project full title	EXPERT – EXpanding Platforms for Efficacious mRNA Therapeutics

Deliverable number	D12.1
Deliverable title	Public project website
Type ¹	DEC
Dissemination level ²	P
Work package number	WP12
Work package leader	EURICE
Author(s)	Holger Jung, Katrin Neisius, Nina Weiler, Melanie Haupenthal, Corinna Hahn (all Eurice), Ray Schiffelers (UMCU) and other partners for content/review
Keywords	Project website, public, visibility, communication, dissemination, information

The research leading to these results has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 825828.

The author is solely responsible for its content, it does not represent the opinion of the European Commission and the Commission is not responsible for any use that might be made of data appearing therein.

¹ **Type:** Use one of the following codes (in consistence with the Description of the Action):

R: Document, report (excluding the periodic and final reports)
 DEM: Demonstrator, pilot, prototype, plan designs
 DEC: Websites, patents filing, press & media actions, videos, etc.
 OTHER: Software, technical diagram, etc.

² **Dissemination level:** Use one of the following codes (in consistence with the Description of the Action)

PU: Public, fully open, e.g. web
 CO: Confidential, restricted under conditions set out in the Model Grant Agreement
 CI: Classified, information as referred to in Commission Decision 2001/844/EC

Table of Contents

1. Introduction.....	4
2. Features of the Website	4
3. Conclusion	4
4. Annex - Screenshots	5

1. Introduction

The EXPERT public website is the project's predominant tool for communication about the project and, in the end, for disseminating results aiming at reaching a broad public as well as stakeholders and scientists in the field and creating continuous awareness of the project's activities.

The EXPERT public website is part of WP12 "Intellectual Property, Dissemination and Exploitation of Results". This WP's objectives concentrate largely on ensuring coherent external communication of project activities, progress and achievements, and on ensuring optimal visibility and wide outreach to all relevant stakeholders and the scientific community.

The public website went online in M2 of the project's duration on October 29, 2019. It has been developed by a professional communications team at Eurice together with the coordinator and feedback from all partners. It is in line with the project's corporate identity and its set-up ensures that the site is appealing, efficient and easy to use. It will constantly be updated with information that becomes available and will continuously be adapted to the project's requirements.

The website can be accessed via <http://expert-project.eu/>.

2. Features of the Website

The EXPERT website is directed at different stakeholders with an interest in the project, its activities as well as its outcomes, innovations and progress. Such stakeholders include the scientific community, Industry, regulatory authorities, patient organisations and clinicians, and the general public. In addition to the general information provided on the website, the consortium will endeavour to address the stakeholders with individual content.

For a start, the website offers a project introduction including the vision and key facts of EXPERT. In addition, it offers background information about the project as well as about the consortium members. There is also a section on project-related news and events. Finally, contact details, imprint and a privacy statement are included.

The different sections are available in the tabs in the main navigation with drop-down menus to subpages.

News and events are announced on the homepage.

The project website currently offers the following features and information (provided as screenshots in the Annex):

- (1) Home:** Main page and entry point to the EXPERT website providing key facts, a short intro and the partners involved in the project
- (2) About:** Basic information about the project, its objectives and the approach
- (3) Partner:** Presentation of the EXPERT partner institutions and their team
- (4) News & Events:** Frequently updated section with news and events from within the consortium and generated from subject-related content

3. Conclusion

The website is online and functional and provides all relevant features to inform the interested user about the project. As the development of the website is a continuous task, the website as presented in this deliverable must be considered to only be a 'snapshot'. Content will be regularly updated. Additional information and subpages will be introduced, if needed.

4. Annex - Screenshots

(1) Home



OFF-THE-SHELF mRNA NANOMEDICINES

[About](#) [Partners](#) [News & Events](#)



DURATION
60 months



FUNDING
14.9 Mio €



PARTNERS
11

VISION

EXPERT aims at developing a new off-the-shelf delivery system for RNA-based nanomedicines to treat cancer and cardiovascular disease. In the long term, the platform technology could be used for improving diagnostic and therapeutic options for patients with several other diseases.



DESIGN



PRODUCTION



SAFETY & EFFICACY



CLINICAL STUDY

“Our vision is to complement existing clinical studies with mRNA therapeutics and to overcome some of the main obstacles mRNA-based therapy approaches are facing on their way to the market. The EXPERT approach could substantially lower the costs of such treatments enabling their use for more patients and different types of diseases.”



Raymond Schiffelers
EXPERT Coordinator

[Contact](#) [Imprint](#) [Privacy](#) [Intranet](#) 



The EXPERT project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 825828.

(2a) About / Key Facts



OFF-THE-SHELF mRNA NANOMEDICINES

[About](#) [Partners](#) [News & Events](#)

Key Facts

EXPERT aims at developing a new off-the-shelf delivery system for RNA-based nanomedicines to treat cancer and cardiovascular disease. In the long term, the platform technology could be used for improving diagnostic and therapeutic options for patients with several other diseases.

Icon	Value
	DURATION 60 months
	FUNDING 14.9 Mio €
	PARTNERS 11


Countries involved

Country	Country	Country	Country	Country
				
The Netherlands	Sweden	Belgium	Norway	Ireland
				
Hungary	Israel	France	Spain	Germany

[Contact](#) [Imprint](#) [Privacy](#) [Intranet](#)

 The EXPERT project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 825828.

(2b) About / Objectives

A mockup of the EXPERT project website. The header features the EXPERT logo (a syringe icon with the word EXPERT) and the text 'OFF-THE-SHELF mRNA NANOMEDICINES'. Below the header is a navigation bar with links for 'About', 'Partners', and 'News & Events'. The main content area is titled 'Challenges' and lists three major challenges: achieving functional target tissue delivery, reaching target cell cytoplasm, and circumventing adverse immune responses. Below this is a 'Project Objectives' section with five bullet points: development of mRNA nanomedicines, production in a quality-by-design (QbD) approach, Good Manufacturing Practice scale-up and clinical translation, first-in-man clinical study, and investigation for heart failure patients. The footer includes links for 'Contact', 'Imprint', 'Privacy', and 'Intranet', along with the European Union flag and a statement about funding from the Horizon 2020 programme.

(2c) About / Approach



OFF-THE-SHELF mRNA NANOMEDICINES

[About](#) [Partners](#) [News & Events](#)

Approach

The complementary expertise of the partners spans the entire development track from nanoparticle design via Good Manufacturing Practice (GMP)-based production to clinical expertise.



DESIGN

PRODUCTION

SAFETY & EFFICACY

CLINICAL STUDY

Design

EXPERT will design modular nanocarriers consisting of an mRNA payload, nanocarriers materials and, where applicable, a targeting ligand. The mRNA payload is a fragile molecule that bears the therapeutic activity. It can easily be destroyed by enzymes and has difficulties in reaching the site of activity. Therefore, the consortium will investigate the use materials to protect and deliver the mRNA, including established, emerging and exploratory components which could be suitable for GMP production.

Production

The modular nanocarriers will be manufactured through quality-by-design with excellent control over the physicochemical parameters, repeatability and scalability which is compatible with GMP production. To remove operator variability, enable seamless scale-up and allow for robust manipulation of a single variable per experiment, EXPERT will have microfluidics manufacture at all partners' research sites. The well-characterised, reproducible nanocarriers will subsequently be validated for safety and efficacy in in vitro and in vivo experiments.

Safety & Efficacy

To evaluate the performance, EXPERT will investigate the tissue distribution, cellular targeting and cytoplasmic translocation of promising modular nanocarriers. A pre-clinical in vitro and in vivo safety assessment as well as in vivo checks of the mRNA nanomedicine translation will help to analyse the therapeutic efficacy in order to select the best mRNA formulation to be applied in a first clinical study.

Clinical Study

As proof-of-concept, the partners aim at a first in-man clinical study focusing on immunotherapy for metastatic triple-negative breast cancer, a subtype with high risk of relapse. In these patients, the primary lesion will be injected with the immune stimulatory mRNA nanomedicine while closely monitoring local and systemic adverse effects. After removing the tissue, the researchers will investigate immune cell recruitment as a surrogate marker of efficacy.

[Contact](#) [Imprint](#) [Privacy](#) [Intranet](#) 



The EXPERT project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 825828.

(3) Partner

EXPERT

OFF-THE-SHELF mRNA NANOMEDICINES

[About](#) [Partners](#) [News & Events](#)

EXPERT Partners

- [University Medical Centre Utrecht](#)
- [AstraZeneca](#)
- [eTheRNA immunotherapies](#)
- [SINTEF](#)
- [Trinity College Dublin](#)
- [Semmelweis University](#)
- [Tel Aviv University](#)
- [CYBERNANO](#)
- [Karolinska Institutet](#)
- [CIDEFEC](#)
- [European Research and Project Office Gribbi](#)

[Contact](#) [Imprint](#) [Privacy](#) [Intranet](#)

The EXPERT project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 825828.

(3a) Partner – subpage

The screenshot shows a website for the EXPERT project, specifically the partner subpage for Eurice GmbH. The page has a blue background with molecular structure graphics in the corners. At the top, there is a logo for EXPERT (a syringe icon) and the text "OFF-THE-SHELF mRNA NANOMEDICINES". Below this are navigation links: "About", "Partners", and "News & Events". The main heading is "European Research and Project Office GmbH (EURICE)". A paragraph describes Eurice's role, founded in 2000, providing support services for large international collaborative projects. To the right of this text is a small Eurice logo and a "Website" link. Below the description is a section titled "Role within EXPERT" explaining their support in project management. This is followed by "Main Contacts" with three entries, each featuring a circular profile picture, name, title, and an "Email" link. At the bottom left is a "← CIDETEC" button. The footer contains links for "Contact", "Imprint", "Privacy", and "Intranet", along with a European Union flag and text stating the project is funded by the Horizon 2020 programme under grant agreement No 825828.

EXPERT
OFF-THE-SHELF mRNA NANOMEDICINES

[About](#) [Partners](#) [News & Events](#)

European Research and Project Office GmbH (EURICE)

Founded in the year 2000, the European Research and Project Office GmbH (Eurice) provides comprehensive support services for the planning, initiation, and implementation of large international collaborative projects. Eurice has been involved in EU-Framework Programmes since FP4 and has been supporting researchers in over 250 EU funded projects to date. Today, Eurice is among Germany's largest project management offices, with a dedicated team of 40 staff members with different professional and scientific expertise, such as law, medicine, biology, chemistry, communications, information sciences, or computer sciences. In addition to classical project management, Eurice helps to develop and implement coherent IP strategies and supports consortia through dissemination, networking, training, and capacity building activities.



[Website](#)

Role within EXPERT

Within the EXPERT project, Eurice will support the consortium in all aspects of project management including administrative, legal and financial matters, to ensure a smooth project implementation. To maximise project impact, Eurice will drive outreach and communication activities of the project.

Main Contacts



Melanie Hauptenthal, Senior Project Manager
[Email](#)



Corinna Hahn, Senior Research and Innovation Manager
[Email](#)



Ulrike Waltschott, Communication Manager
[Email](#)

[← CIDETEC](#)

[Contact](#) [Imprint](#) [Privacy](#) [Intranet](#)

 The EXPERT project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 825828.

(4) News & Events

